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Increased neurokinin-1 receptor availability in the amygdala in
social anxiety disorder: a positron emission tomography study
with [11C]GR205171
A Frick1, F Ahs1,2, C Linnman3, M Jonasson4, L Appel4, M Lubberink4, B Långström5, M Fredrikson1,2,6 and T Furmark1,6
The neurokinin-1 (NK1) receptor is abundantly expressed in the fear circuitry of the brain, including the amygdala, where it
modulates stress and anxiety. Despite its proposed involvement in psychopathology, only a few studies of NK1 receptor availability
in human subjects with anxiety disorders exist. Here, we compared NK1 receptor availability in patients with social anxiety disorder
(SAD; n= 17) and healthy controls (n= 17) using positron emission tomography and the radiotracer [11C]GR205171. The Patlak
Graphical plot using a cerebellar reference region was used to model the inﬂux parameter, Ki measuring NK1 receptor availability.
Voxel-wise statistical parametric mapping analyses revealed increased NK1 receptor availability speciﬁcally in the right amygdala in
SAD patients relative to controls. Thus, we demonstrate that exaggerated social anxiety is related to enhanced NK1 receptor
availability in the amygdala. This ﬁnding supports the contribution of NK1 receptors not only in animal models of stress and anxiety
but also in humans with anxiety disorders.
Translational Psychiatry (2015) 5, e597; doi:10.1038/tp.2015.92; published online 7 July 2015
INTRODUCTION
While activity patterns in the neural fear circuitry, including the
amygdala, hippocampus, anterior cingulate cortex and insula are
altered in anxiety conditions,1 the neurochemical underpinnings
of these disabling and common2 psychiatric disorders are not fully
understood. The neuropeptide substance P (SP) and its preferred
neurokinin-1 (NK1) receptor3,4 are abundantly expressed in the
brain’s fear circuit,5 and have been suggested to have a role in
anxiety disorders.6–8 The evidence mainly stems from animal and
pharmacological intervention studies showing that the SP/NK1
system in the amygdala modulates stress and anxiety.6,9 For
example, stress increases the release of SP in the amygdala in
rats.9 Consistently, in humans, patients with posttraumatic stress
disorder (PTSD) exhibit elevated cerebrospinal ﬂuid SP concentra-
tions that are further heightened by symptom provocation.10 Also,
exposure to phobic stimuli reduces the binding of the radi-
olabeled NK1 receptor antagonist GR205171 in the amygdala in
patients with speciﬁc phobia, consistent with displacement of the
tracer by stress-induced endogenous SP release.11
Moreover, in animals, administration of SP into the amygdala
has anxiogenic effects,9,12 whereas pharmacological blockage of
the NK1 receptor is associated with decreased anxiety-like
behavior.6,9 Similarly, in healthy human subjects, NK1 antagonists
have anxiolytic effects.13 Also, in patients with social anxiety
disorder (SAD), treatment with the selective NK1 antagonist
GR205171 alleviates clinical symptoms and attenuates anxiety-
induced regional cerebral blood ﬂow in the amygdala.14 However,
it should be noted that treatment ﬁndings from clinical trials
of NK1 antagonists for psychiatric disorders are mixed.15–20
Collectively, ﬁndings both in animals and humans support that
SP, acting through NK1 receptors, is anxiogenic.
Although there is ample evidence that the SP/NK1 system is
involved in anxiety, not much is known about NK1 receptor
availability in patients with anxiety disorders. To the best of our
knowledge, only one positron emission tomography (PET)
imaging study on this topic has been published to date, in which
Fujimura and colleagues reported a widespread decrease of NK1
receptor availability in patients with panic disorder as compared
with healthy control individuals.21
SAD, one of the most common anxiety disorders with a life-time
prevalence of 10–15%,2 is associated with a hyperactive
fear circuit, most consistently the amygdala, during anxiety
provocation22 and emotional perception.23 Given the role of the
SP/NK1 system in stress and anxiety, and because treatment with
NK1 receptor antagonists has shown promising initial results in
SAD, including attenuation of stress-related amygdala activity,14 it
could be hypothesized that this disorder is associated with altered
NK1 receptor availability particularly in the amygdala. The aim of
the present study was therefore to examine NK1 receptor
availability in SAD patients as compared with healthy controls
(HCs) using PET and the highly selective NK1 receptor antagonist
radiotracer [11C]GR205171.24
MATERIALS AND METHODS
Participants
Eighteen SAD patients and 18 age- and sex-matched HCs were included.
Due to technical problems, data from one participant in each group could
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not be analyzed, leaving 17 participants with SAD (nine women; mean±
s.d. age: 30.9 ± 7.3 years) and 17 HCs (nine women; mean± s.d. age:
34.6 ± 9.8 years). Participants were recruited through newspaper advertis-
ing. Initial screening consisted of social anxiety questionnaires and a brief
telephone interview including self-report of alcohol consumption during
the last month. The anxiety disorder questions from the Structured Clinical
Interview for DSM-IV disorders25 was thereafter administered by a clinical
psychologist. Duration of SAD symptoms was assessed through self-report.
In addition, to exclude other serious psychiatric disorders, a psychiatrist
administered the Mini International Neuropsychiatric Interview26 and a
medical examination was conducted.
All patients met the DSM-IV27 criteria for SAD and exhibited marked
public speaking anxiety. Social anxiety symptom severity was measured
using the Liebowitz Social Anxiety Scale Self-Report version (LSAS-SR).28 Six
of the SAD patients fulﬁlled criteria for a comorbid psychiatric disorder,
four for general anxiety disorder, one for speciﬁc phobia and one for both
generalized anxiety disorder and speciﬁc phobia, and one patient had a
history of major depressive disorder. Four patients had a history of
treatment with selective serotonin re-uptake inhibitors, and two with
propranolol. One patient still used propranolol occasionally before
entering the study, while all other patients were free of psychotropic
medication for at least 6 months. None of the HCs met criteria for previous
or current psychiatric disorder.
Main exclusion criteria were current primary psychiatric disorder other
than SAD, alcohol/drug abuse, neurological disorder, somatic disease,
ongoing treatment for SAD or treatment terminated within 6 months,
chronic use of prescription medication, left handedness, previous PET
examination, family history of cancer and for women also pregnancy and
menopause.
PET image acquisition
PET image acquisition was performed using an ECAT Exact HR+ PET
scanner (Siemens/CTI, Knoxville, TN, USA) with an axial ﬁeld of view of
155mm. Subjects fasted 3 h and refrained from alcohol, caffeine and
tobacco 12 h before the PET investigation, assessed by self-report.
Subjects were positioned supine in the PET scanner with their heads
lightly ﬁxated and a venous catheter was inserted. A 10-min transmission
scan was performed using three retractable germanium (68Ge) rotating line
sources. After the transmission scan, [11C]GR205171 was injected
intravenously as a fast bolus simultaneously with the start of the emission
scan. [11C]GR205171 is a selective NK1 receptor antagonist with
subnanomolar afﬁnity to the receptor as well as rapid uptake in the
brain.24,29,30 Subjects rested during image acquisition. Data were acquired
in three-dimensional mode and consisted of 17 frames (4 × 60 s, 3 × 120 s,
10 × 300 s) with a total duration of 60min. The SAD group received on
average 378.6 (SD: 25.0) MBq, equal to 5.4 (SD: 1.1) MBq kg− 1 body weight,
and the HC group received 398.1 (SD: 11.3) MBq, equal to 5.6 (SD: 1.1)
MBq kg− 1 body weight. In addition, a [15O]water PET scan used for spatial
normalization was acquired (three frames× 30 s) with the administration of
~ 10MBq kg− 1 body weight. Both SAD patients and HC participants
underwent the same investigations.
Image analysis
Parametric images showing inﬂux rate Ki (ml cm
− 3 min− 1) of [11C]
GR205171 for each voxel, that is, an index of NK1 receptor availability,
were calculated using a modiﬁed Patlak Graphical plot with cerebellum as
reference region11,31,32 using the time interval of 30–60min. The
cerebellum was chosen as the reference region as it displays a paucity
of NK1 receptors.17,24,33 Deﬁnition of cerebellum was performed using the
[15O]water PET scan of each participant and PVElab software,34 an
observer-independent approach for automatic generation of volumes of
interest.
Each individual’s [11C]GR205171 Ki image was co-registered to their [
15O]
water summation image using afﬁne transformation. The [15O]water
summation image was then normalized to the PET template from
Statistical Parametric Mapping 8 (Wellcome Department of Cognitive
Neurology, University College London, www.ﬁl.ion.ucl.ac.uk), and the
calculated transformation parameters applied to the [11C]GR205171 Ki
image, resulting in [11C]GR205171 Ki images normalized to the Montreal
Neurological Institute standard space with isotropic 2 × 2× 2mm3 voxels.
The Montreal Neurological Institute-normalized [11C]GR205171 Ki images
were subsequently smoothed with a 12-mm isotropic Gaussian kernel.
Data transformation
Alcohol consumption was recoded into consumed centiliters of 40%
alcohol last month. One beer was counted as 6.25 cl of 40% alcohol and
one bottle of wine as 22.5 cl. Two SAD patients did not provide data that
could be recoded, that is, they did not quantify their alcohol consumption.
Statistical analysis
Anatomical regions of interest (ROIs) were chosen a priori on the basis of
earlier neuroimaging ﬁndings in SAD and included nodes in the brain fear
circuitry: the amygdala, hippocampus, insular cortex and anterior
cingulate cortex.1 ROIs were deﬁned using the Automated Anatomical
Labeling library from the Wake Forest University Pickatlas.35 In addition, a
whole-brain exploratory analysis was performed.
Statistical analyses were conducted using Statistical Parametric Mapping
8. Group differences in NK1 receptor availability between SAD patients and
HC participants were assessed using two-sample t-tests. To explore the
relationship between social anxiety symptom severity and NK1 receptor
availability within the SAD group, parametric [11C]GR205171 Ki images
were entered into a regression model with LSAS-SR total score as predictor.
Age and sex were entered as covariates in all the analyses, as there
are known effects of age and sex on NK1 receptor availability.36,37
For ROI analyses, the statistical threshold for signiﬁcance was set to
Po0.05 family-wise error (FWE) corrected for multiple comparisons within
the ROIs, and for the exploratory whole-brain analysis the statistical
threshold was set at Po0.001 uncorrected to not miss small differences in
NK1 receptor availability. Follow-up analyses of ROIs displaying signiﬁcant
group differences were conducted to calculate the mean percent
difference between the SAD and HC groups using the mean NK1 receptor
availability within the whole anatomically deﬁned ROIs.
Behavioral data and participant characteristics were analyzed using R
3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).
Ethical statement
The study was approved by the Uppsala University Medical Faculty Ethical
Review Board and the Radiation Ethics Committee at Uppsala University
Hospital. All study participants gave written informed consent before the
study start and were reimbursed for their participation.
RESULTS
LSAS-SR scores were signiﬁcantly higher (t(32) = 13.37, Po0.001)
in the SAD patients (mean± s.d.: 80.6 ± 20.6) than in the HC group
(mean± s.d.: 6.6 ± 5.0). Mean duration of SAD symptoms was 19.4
(9.4) years. The groups did not differ in educational level
(χ2(1) = 0.14, P= 0.71) or alcohol consumption (SAD: mean± s.d.
64.3 ± 86.2 cl; HC: 54.4 ± 54.9; t(30) = 0.40, P= 0.70).
Statistical parametric mapping within the a priori ROIs (the
amygdala, hippocampus, insular cortex and anterior cingulate
cortex) revealed higher NK1 receptor availability in the right
amygdala only (Montreal Neurological Institute x, y, z: 28, − 2, − 20;
Z= 3.79, PFWE = 0.004; 496mm
3) in SAD patients as compared with
HC individuals (see Figure 1). Mean regional NK1 receptor
availability in the right amygdala ROI was 18.5% higher in SAD
patients (mean± s.d.: 0.0128 ± 0.0017) than in HCs (mean± s.d.:
0.0108 ± 0.0018) (t(32) = 3.294, P= 0.002; see Figure 2). The
exploratory whole-brain analysis revealed no additional areas
except for the amygdala cluster present also in the ROI analyses.
There were no signiﬁcant associations between social anxiety
symptom severity and NK1 receptor availability, or between
duration of SAD symptoms and NK1 receptor availability. No
signiﬁcant changes in NK1 receptor availability were noted when
comparing patients with generalized SAD to non-generalized SAD.
Removing patients with psychiatric comorbidity or history of
psychotropic medication did not alter the results, as the right
amygdala uptake remained highly signiﬁcantly different between
patients and controls (Montreal Neurological Institute x, y, z: 28,
− 4, − 20; Z= 3.16, PFWE = 0.03; 104mm
3).
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DISCUSSION
In this PET study, we demonstrate increased amygdala NK1
receptor availability in SAD patients relative to controls, consistent
with a role for NK1 receptors in human anxiety disorders as
suggested by previous animal and human research.6,9,11,14,21
The present ﬁnding of enhanced NK1 receptor availability in the
amygdala is paralleled by previous reports of heightened
amygdala reactivity in SAD during emotional challenges,22,23 in
accordance with the notion that amygdala NK1 receptors are
involved in stress-induced reactions.11 Consistently, NK1 receptor
antagonism in SAD is associated with reduced state anxiety and
attenuated amygdala responses during stressful public speaking.14
The association between fear-related neuronal activity and the SP/
NK1 system is further strengthened by preclinical research
showing that stress-induced activity in fear-relevant regions is
mediated by NK1 receptors, and that NK1 receptor antagonism
attenuates this activity.8 It is also noteworthy that a positive
feedback mechanism is involved in stress-related SP release such
that NK1 activation triggers SP release during stress, leading to
activation of additional neurokinin receptors where SP binds with
low afﬁnity.38 The heightened resting state NK1 receptor
availability in SAD may thus reﬂect an increased capacity for
stress-related upregulation of SP release, and thereby also
exaggerated amygdala activity, consistent with increased SP
release and amygdala activation in response to symptom
provocation in patients with PTSD10,39 and speciﬁc phobia.11,40
Blocking NK1 receptors in patients with comorbid PTSD and
alcoholism increases activity in the ventromedial prefrontal
cortex,41 an area involved in emotion regulation through its
projections to the amygdala42,43 often reported to be hypoactive
in PTSD.44 Intriguingly, single administration of the NK1 antagonist
aprepitant to healthy participants enhances anterior cingulate
cortex and amygdala activity to positive stimuli, but does not
reduce fear-related neural activity,45 possibly due to the need for
prolonged NK1 blockage or stronger negative stimuli. Further
Figure 1. Parametric [11C]GR205171 Ki images showing mean neurokinin-1 (NK1) receptor availability in patients with (a) social anxiety
disorder and (b) healthy controls. The color bar indicates [11C]GR205171 Ki values. (c) Patients with social anxiety disorder showed increased
NK1 receptor availability in the amygdala. Voxels within the amygdala were thresholded at Po0.05, family-wise error corrected for multiple
comparisons. Mean parametric images of [11C]GR205171 Ki and the statistical maps from the group comparison were overlaid on standard MRI
images. All rows depict slices at MNI coordinate (0, − 2, 0). MNI, Montreal Neurological Institute; MRI, magnetic resonance imaging.
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Figure 2. Neurokinin-1 (NK1) receptor availability ([11C]GR205171 Ki)
in the right amygdala in patients with social anxiety disorder (SAD)
and healthy controls. Black horizontal lines denote group averages.
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studies are necessary to determine whether the association
between activity in the SP/NK1 system and fear-related amygdala
responsivity reﬂects a pathophysiological pathway linking neuro-
chemical alterations to exaggerated neural reactivity.
Our ﬁndings of elevated NK1 receptor availability in the right
amygdala of patients with SAD suggest a role for the SP/NK1
system in human anxiety disorders, but stand in contrast to the
ﬁndings of widespread reduction in NK1 receptor availability in
patients with panic disorder.21 Similar discrepancies have been
reported for the serotonin transporter (SERT), that is, SAD is
associated with increased SERT availability,46 whereas in panic
disorder, males, but not females, exhibit elevated SERT
availability.47,48 Moreover, it should be noted that ﬁndings from
clinical trials of NK1 receptor antagonists for mood and anxiety
disorders have been mixed. Initial positive ﬁndings14,20 have been
difﬁcult to replicate in phase III studies.16,17 A proposed reason for
this discrepancy is the lack of sufﬁcient receptor occupancy in
phase III trials.49,50 Furthermore, NK1 receptor blockage may be
selectively effective for symptoms during high stress levels such as
symptom provocation not ordinarily assessed in clinical trials.
Indeed, in a previous report from our lab, NK1 receptor
antagonism reduced state anxiety during stressful public speaking
but not overall social anxiety symptoms in patients with SAD
relative to placebo,14 and in a recent trial of GR205171 for PTSD,
only hyperarousal symptoms were signiﬁcantly improved.19
Interestingly, NK1 receptor antagonists have also shown potential
for treatment of alcohol- and drug-related disorders,41,51,52 that
are often comorbid with mood and anxiety disorders.53,54
Even though the spatial resolution of PET is limited, the location
of the peak voxel, according to the detailed atlas of Mai et al.,55
was in the basolateral amygdala in which NK1 receptor previously
have been linked to anxiety-like behavior.56 As SAD is arguably
associated with heightened stress levels,57 increased NK1 receptor
availability in socially anxious individuals is consistent with animal
research on long-term upregulation of SP receptors in the
amygdala following prolonged restraint stress.58 Indeed, it has
been suggested that stress-induced effects on SP release and NK1
receptor expression could be modulated by stressor duration and
intensity.6,9 We, therefore, argue that the increased binding of
resting [11C]GR205171 in SAD patients is a marker of enhanced
NK1 receptor availability in the amygdala following prolonged
stress, rather than reﬂecting lower endogenous SP concentrations.
However, it remains to be investigated whether enhanced NK1
receptor availability is a risk factor for developing SAD or a
consequence of the disorder.
Furthermore, the SP/NK1 system is frequently co-expressed and
interacts with the serotonin system,59 suggesting that the present
ﬁndings may be linked to compromised brain serotonin function
in SAD and other anxiety disorders.60 Indeed, NK1 receptor
antagonists enhance brain serotonergic cell activity,61 whereas
blocking serotonin re-uptake decreases SP concentrations in fear-
related brain regions including the amygdala.62 The NK1 receptor
also has a role in regulating oxytocin secretion.63 Accordingly, NK1
receptor antagonists,14 selective serotonin re-uptake inhibitors14,64
and oxytocin65 attenuate amygdala responses to emotional
challenge in SAD, suggesting a common ﬁnal pathway for these
potentially anxiolytic agents.
Some limitations of the study deserve mentioning. First, there
was restricted power, due to relatively few participants, to ﬁnd a
relationship between the SP/NK1 system and clinical symptoms at
the behavioral level, although the number of subjects included is a
normal sample size in PET trials. Second, our statistical thresholds
may be perceived as liberal, but it should be noted that the
increase in amygdala NK1 receptor availability survived stringent
Bonferroni correction for number of ROIs analyzed. Also, since the
exploratory analysis revealed no other areas that differed between
groups, the amygdala difference is speciﬁc. Unfortunately,
genotype information was not available, precluding genetic
association analysis, e.g., the recently reported inﬂuence of TACR1
genotype on amygdala NK1 receptor availability.66
In conclusion, we demonstrate increased NK1 receptor avail-
ability in the amygdala of SAD patients. Enhanced SP/NK1
neurotransmission may exaggerate fear-related amygdala activity
and our results may thus help explain previous reports of
enhanced amygdala responses to socioemotional stimuli in
SAD23 and attenuated amygdala reactivity, as well as anxiety
reduction, following NK1 antagonism.14 The ﬁndings support
involvement of the SP/NK1 system not only in animal models of
stress and anxiety6 but also in humans with anxiety disorders.
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